This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
by Stockwatch Business Reporter
The TSX Venture Exchange climbed 10.75 points to 509.01 Friday, ending the week up 16.92
points. Mick Thomson's 10th capital pool shell,
Panorama Capital Corp. (PANO: halted), plans to acquire a U.S. medical device company called
Avisa Pharma Inc. for the shell's qualifying transaction. The shell
will roll back 1 for 3, leaving it with 2,933,333 shares issued, then issue 46,865,040 shares to its target's shareholders.
Avisa was founded in Santa Fe, N.M., in 2010. It holds a licence to commercialize a diagnostic breath test that was developed by the University of New Mexico. The company is working on a device called the Avisa BreathTest, which is designed to detect pneumonia and other pulmonary infections or respiratory diseases within 10 minutes. (The company does not mention COVID-19 or any other coronavirus.) Avisa notes that existing respiratory diagnostic tests, which analyze mucous samples rather than breath samples, can take up to three days.
The remainder is available to Stockwatch subscribers.
© 2020 Canjex Publishing Ltd. All rights reserved.